Mireille Mousseau

Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma

Sylvie Négrier, Bernard Escudier, Christine Lasset et al. · New England Journal of Medicine · 1998 · 965 citations · Full text

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

Xavier Pivot, Joseph Gligorov, Volkmar Müller et al. · Annals of Oncology · 2014 · 169 citations · Full text

Breast Oncology, Oncology, Conventional Intravenous Infusion +6

Rotenone Inhibits the Mitochondrial Permeability Transition-induced Cell Death in U937 and KB Cells

Christiane Chauvin, Frédéric De Oliveira, Xavier Ronot et al. · Journal of Biological Chemistry · 2001 · 135 citations · Full text

Mitophagy, Cell Death, Redox Biology +16

New advances in DPYD genotype and risk of severe toxicity under capecitabine

Marie-Christine Étienne-Grimaldi, Jean-Christophe Boyer, Christophe Béroud et al. · PLoS ONE · 2017 · 102 citations · Full text